Law360, New York (March 31, 2009, 12:00 AM ET) -- Bayer AG has asked a judge to expand his dismissal of fraud claims in three suits to include others in the multidistrict litigation over the blood-clotting drug Trasylol, which Bayer pulled from the market after studies indicating potentially fatal side effects came to light.
Bayer on Monday requested that a March 5 order dismissing common law fraud claims in three individual complaints and a constructive fraud claim in the master complaint be applied to those claims in other cases before the United States District Court for...
Bayer Wants More Fraud Claims Nixed In Trasylol MDL
To view the full article, take a free trial now.
